Introduction
============

Bisphosphonates are widely used clinically for the treatment of osteoporosis and bone metastasis. Although they primarily target osteoclasts, adverse and beneficial effects on other organ systems have been described. Destruction of the gastric epithelium by high concentrations of bisphosphonates is a recognized off-target effect. On the contrary, beneficial effects on atherosclerosis have also been described,[@b1-dddt-10-1453]--[@b3-dddt-10-1453] although the precise mechanisms involved have not been elucidated.

Migration and proliferation of vascular smooth muscle cells (VSMCs) play key roles in the development of vascular proliferative diseases such as atherosclerosis and restenosis.[@b4-dddt-10-1453] Moreover, previous studies showed that bisphosphonates inhibit adhesion of VSMCs to extracellular matrix components in tissue culture, as well as their proliferation and migration.[@b5-dddt-10-1453],[@b6-dddt-10-1453] The end result is decreased neointimal hyperplasia both in preclinical and clinical investigations.[@b7-dddt-10-1453]--[@b9-dddt-10-1453] MMPs play a variety of roles in normal vascular physiology and pathology. For example, increased expression of MMP-13 (especially in rodents) can degrade fibrillar type I and III collagen, thereby increasing atherosclerotic plaque's vulnerability to rupture.[@b10-dddt-10-1453] Conversely, MMP-2 and MMP-9 stimulate migration and proliferation of VSMCs by degrading basement components including type IV collagen. This contributes to restenosis but may prevent plaque rupture thanks to formation of a more stable plaque cap.[@b11-dddt-10-1453]

Bisphosphonates have been reported to inhibit expression and activity of some MMPs in different steps of cancer progression.[@b12-dddt-10-1453]--[@b14-dddt-10-1453] However, the effects of bisphosphonates on MMPs implicated in the pathogenesis of atherosclerosis and restenosis have not been elucidated. In this study, we therefore investigated the effects of zoledronate, which is a highly potent bisphosphonate, on MMP-2, MMP-9, and MMP-13 expressions in rat VSMCs.

Materials and methods
=====================

Cell culture
------------

### Primary rat cells

Male Sprague Dawley rats were killed by cervical dislocation in accordance with the Directive 2010/63/EU of the European Parliament. Approval was granted by the University of Bristol ethical review board. VSMCs (four separate preparations from different rats) were obtained by the explant method from thoracic aortas and were cultured in Dulbecco's Modified Eagle's Medium (Lonza, Basel, Switzerland) containing 10% fetal calf serum (FCS), penicillin (100 mg/mL), streptomycin (100 U/mL), and L-glutamine (2 mM). VSMCs were used between passage 6 and 8 in the experiments, which is within the limits (passage 3--8) of previous studies.[@b15-dddt-10-1453] Reduced serum (2%) or serum-free conditions were used in some incubations to avoid interfering with the zymographic assays, and were well tolerated by VSMCs.[@b16-dddt-10-1453]

### Treatment of the cells

Zoledronate (Novartis International AG, Basel, Switzerland) was obtained as a 2.94 mM sterile, neutral aqueous solution for intravenous infusion containing 4 mg of zoledronate, 220 mg mannitol, and 24 mg sodium citrate in 5 mL. Cells were seeded into 12-well plates. When they became confluent, they were pre-treated with zoledronate to a final concentration of 100 μM zoledronate or kept as untreated in 2% FCS containing medium for 24 hours. Given the high dilution and innocuous nature of the vehicle, untreated cells were used as a control. Cells were stimulated by PDGF (50 ng/mL) plus TNF-α (10 ng/mL) or left unstimulated for a further 24 hours in serum-free medium. In other series of experiments, cells were pre-treated either with SC-514 (Cayman Chemicals MA, USA), (50 μM)[@b17-dddt-10-1453] or with apocynin (20 nM) for 2 hours, then zoledronate (100 μM) was added into 2% FCS containing medium for 24 hours.

Real-time polymerase chain reaction (PCR) analysis
--------------------------------------------------

Total RNA were extracted from VSMCs using the total RNA extraction kit (Ambion, Thermo Fisher Scientific, Waltham, MA, USA), according to the manufacturer's instructions. Extracted RNA was quantified using Nanodrop™ 1000 Spectrophotometer (Thermo Fisher Scientific) and reverse transcribed using a Roche Reverse Transcription Kit (Hoffman-La Roche Ltd., Basel, Switzerland) (100 ng RNA per reaction). A genomic DNA removal step was included, and the resulting cDNA was diluted in 10 mM Tris-HCl, pH 8. Real-time quantitative PCR was performed in Illumina Eco Real-Time PCR with Roche SYBR Green Master Mix and primers for MMP-2, MMP-9, MMP-13, IκB, and 36B4, which is a housekeeping gene. Primers are listed in [Table 1](#t1-dddt-10-1453){ref-type="table"}. To confirm amplification specificity, PCR products from each primer pair were subjected to agarose gel electrophoresis. Relative mRNA expression levels were calculated by using the Delta-Delta Ct method using 36B4 as a normalization control.

Western blotting and gelatin zymography
---------------------------------------

Conditioned media of the cells were collected and concentrated using centrifugal filter units (Merck Millipore, Billerica, MA, USA). Cells were lysed in sodium dodecyl sulfate (SDS) buffer (2% SDS \[w/v\], 16% glycerol \[v/v\], and 50 mM Tris \[pH 6.8\]). Protein concentration in lysates was measured using BCA Protein Assay Kit (Thermo Fisher Scientific) and was used to normalize loading of gels.

MMP-9 activity in conditioned medium was determined by gelatin zymography as described previously.[@b17-dddt-10-1453] Briefly, 7.5% polyacrylamide gels containing 2 mg/mL of gelatin were subjected to electrophoresis. Following electrophoresis, SDS was removed by washing in 2.5% Triton X-100. Gels then were incubated at 37°C for 48 hours in incubation buffer (50 mM Tris-HCl, pH 8.0, 50 mM NaCl, 10 mM CaCl~2~, and 0.05% Triton X-100). Ethylenediaminetetraacetic acid (EDTA) inhibits MMP activity by chelating Zn^2+^ on enzymes' catalytic domain. In order to verify if the detected bands were MMP-2 and -9, another gel was incubated in calcium-free incubation solution containing 10 mM EDTA. After the incubation period, gels were stained in 0.2% Coomassie Brilliant Blue. Images of the gels were captured with a scanner. Gelatinase activity was detected as clear bands on dark backgrounds.

For Western blotting, equal total protein concentrations (see above) were loaded on 8%--10% polyacrylamide gels and transferred onto polyvinylidene difluoride membranes as described previously.[@b18-dddt-10-1453] These were blocked for an hour in 5% (w/v) skimmed milk powder and incubated overnight at 4°C with anti-MMP-13 (catalog no ab39012; Abcam, Cambridge, UK) (1:2,000 in 5% BSA:Tris-buffered saline). Bound primary antibodies were detected by horseradish peroxidase-conjugated antibodies (Sigma-Aldrich Co., St Louis, MO, USA; catalog no A6154) (1:5,000 in 5% BSA:Tris-buffered saline) and enhanced chemiluminescence (Amersham International, Buckinghamshire, UK).

Detection of reactive oxygen species (ROS) in rat thoracic aortic rings
-----------------------------------------------------------------------

This study was approved by the Local Ethics Committee of Dokuz Eylul University School of Medicine. All animals received care in compliance with the principles of laboratory animal care formulated by the National Society for Medical Research and with the Guide for the Care and Use of Laboratory Animals prepared by the Institute of Laboratory Animal Resources.

Levels of superoxide anion and other ROS in aortic rings were measured as previously described.[@b19-dddt-10-1453] In this study, Wistar rats were euthanized by decapitation under ketamine/xylazine anesthesia. The thoracic aorta segment was dissected. Following careful removal of loose connective tissue, thoracic aorta was cut into 2 mm rings. The rings were then transferred into Dulbecco's Modified Eagle's Medium/F12 (Gibco, Thermo Fisher Scientific) cell culture medium containing 2% FCS immediately. The rings were incubated in cell culture medium in the presence or absence of 100 μM zoledronate for 24 hours in a humidified atmosphere containing 5% CO~2~ at 37°C. Subsequently, aortic rings were transferred to solid white well plates containing 200 mL of HEPES-buffered Krebs-Henseleit solution (pH 7.4). After addition of chemiluminescence enhancers, lucigenin or luminol (final concentration of 5 μmol/L for either), ROS were quantified using a multi-plate reader (Victor III-1420; PerkinElmer Inc., Waltham, MA, USA). Counts were obtained every 10 seconds and normalized per mg of wet tissue weight. Results were expressed as the area under curve for a counting period of 5 minutes of relative light units (rlu)/wet tissue (mg).

Statistical analysis
--------------------

Statistical analyses were performed using the Prism software v.4 (GraphPad Software, Inc., La Jolla, CA, USA). Multiple comparisons were subjected to one-way analysis of variance followed by post hoc Bonferroni correction. Paired Student's *t*-tests were performed to compare means of lucigenin/luminol measurements. When necessary, data were normalized by log transformation. Normalized data were expressed as mean ± standard error of the mean *P*≤0.05 was considered statistically significant.

Results
=======

Effects of zoledronate on expression of MMPs with and without induction by PDGF and TNF-α
-----------------------------------------------------------------------------------------

Because of their diverse roles and regulation patterns, we studied constitutively expressed gelatinase, MMP-2, together with another gelatinase, MMP-9, and a collagenase, MMP-13, that could be induced by a combination of PDGF and TNF-α.

### Gelatinase A/MMP-2

MMP-2 was constitutively expressed in VSMCs ([Figure 1A, B](#f1-dddt-10-1453){ref-type="fig"}), in agreement with previous studies.[@b16-dddt-10-1453] Zoledronate pre-treatment did not change constitutive MMP-2 mRNA levels ([Figure 1A](#f1-dddt-10-1453){ref-type="fig"}). PDGF plus TNF-α treatment significantly decreased MMP-2 mRNA levels to a similar extent in untreated and zoledronate pre-treated cells ([Figure 1A](#f1-dddt-10-1453){ref-type="fig"}). This was confirmed by zymography in which MMP-2 appeared as a major 72 kDa band ([Figure 1B](#f1-dddt-10-1453){ref-type="fig"}) that disappeared on incubation in the presence of EDTA (lower panel).

### Gelatinase B/MMP-9

MMP-9 was expressed at barely detectable levels in quiescent VSMCs ([Figure 1B, C](#f1-dddt-10-1453){ref-type="fig"}) also in agreement with previous work.[@b16-dddt-10-1453] However, zoledronate pre-treatment significantly increased MMP-9 mRNA levels ([Figure 1C](#f1-dddt-10-1453){ref-type="fig"}). PDGF plus TNF-α induced even higher MMP-9 mRNA levels and this effect was enhanced by zoledronate pre-treatment ([Figure 1C](#f1-dddt-10-1453){ref-type="fig"}). Consistent with this, only after PDGF plus TNF-α induction of zoledronate pre-treated cells was MMP-9 protein detectable by zymography as a 92 kDa band ([Figure 1B](#f1-dddt-10-1453){ref-type="fig"}) that disappeared on incubation in the presence of EDTA (lower panel).

### Collagenase 3/MMP-13

The effects of zoledronate on MMP-13 expression were similar to those on MMP-9. Zoledronate pre-treatment significantly increased MMP-13 mRNA and protein levels in control cells ([Figure 1D, E](#f1-dddt-10-1453){ref-type="fig"}). PDGF plus TNF-α induction increased MMP-13 mRNA and protein levels even further, and these were additively increased in zoledronate treated cells ([Figure 1D, E](#f1-dddt-10-1453){ref-type="fig"}).

Role of NF-κB in MMP-9 and MMP-13 induction
-------------------------------------------

The NF-κB pathway was previously shown to play an essential role in up-regulation of MMP-1, MMP-3, and MMP-9 in rabbit and human VSMCs using gene transfer of a dominant negative form of the inhibitor of κB, IκBα.[@b16-dddt-10-1453] We also showed[@b17-dddt-10-1453] that induction of several MMPs in human monocytes can be reversed by using SC-514, which is a selective inhibitor of IκB kinase 2.[@b20-dddt-10-1453] We therefore used SC-514 to investigate whether NF-κB also mediates MMP-9 and MMP-13 up-regulation in rat VSMCs. SC-514 had no effect on the barely detectable levels of MMP-9 ([Figure 2A](#f2-dddt-10-1453){ref-type="fig"}) or MMP-13 ([Figure 2B](#f2-dddt-10-1453){ref-type="fig"}) mRNA in dimethyl sulfoxide treated cells. However, SC-514 strongly inhibited induction of MMP-9 and MMP-13 by PDGF plus TNF-α, thereby demonstrating the importance of NF-κB in up-regulation of both these MMPs. To investigate whether zoledronate activated the NF-κB pathway in VSMCs, we measured expression of IκBα mRNA because its promoter is a direct target of NF-κB activation in a process designed to cause feedback inhibition.[@b21-dddt-10-1453] Detectable levels of IκBα mRNA were present in quiescent VSMCs ([Figure 2C](#f2-dddt-10-1453){ref-type="fig"}) but, similarly to MMP-9 and MMP-13, these were significantly augmented by pretreatment with zoledronate ([Figure 2C](#f2-dddt-10-1453){ref-type="fig"}). PDGF plus TNF-α increased IκBα mRNA levels even further and this was also enhanced by zoledronate pre-treatment ([Figure 2C](#f2-dddt-10-1453){ref-type="fig"}).

ROS production in zoledronate treated isolated VSMCs and aortas
---------------------------------------------------------------

The NF-κB pathway is known to be sensitive to ROS production in VSMCs, independently of the effects of inflammatory mediators.[@b22-dddt-10-1453] We therefore investigated whether ROS production in response to zoledronate might be responsible for activation of the NF-κB pathway, and hence MMP-9 and MMP-13 induction. Firstly, to confirm the activation of ROS, a dichlorofluorescein assay was performed to quantify cellular oxidative stress in isolated rat VSMCs. The cells were treated with zoledronate or PDGF plus TNF-α, with untreated cells as control. The results showed clearly that zoledronate treatment increased ROS levels, whereas no significant effect was observed with PDGF plus TNF-α ([Figure 3A](#f3-dddt-10-1453){ref-type="fig"}). For further confirmation, ROS levels were measured by using lucigenin or luminol in intact rat aortic tissue studied ex vivo. Incubation of rat aortic rings with zoledronate (100 μM) for 24 hours significantly elevated lucigenin enhanced chemiluminescence by approximately 2.5 times compared to control, untreated aortic rings ([Figure 3B](#f3-dddt-10-1453){ref-type="fig"}). The data for luminol enhanced chemiluminescence showed the same trend but was not significant (*P*=0.116, [Figure 3B](#f3-dddt-10-1453){ref-type="fig"}).

Effects of NADPH oxidase inhibitor, apocynin, on induction of MMP-9, MMP-13, and IκB mRNAs
------------------------------------------------------------------------------------------

NADPH oxidase is a prominent source of ROS in VSMCs.[@b23-dddt-10-1453] We therefore investigated the effects of apocynin, which is an inhibitor of NADPH oxidase. Apocynin reversed the elevation of MMP-9 mRNA levels in zoledronate pre-treated cells but had no significant effect on untreated cells ([Figure 4A](#f4-dddt-10-1453){ref-type="fig"}). Apocynin significantly decreased MMP-13 mRNA levels in untreated cells, and also normalized the high levels of MMP-13 mRNA expression in zoledronate pre-treated cells ([Figure 4B](#f4-dddt-10-1453){ref-type="fig"}). Furthermore, apocynin significantly inhibited NF-κB activation measured by the increase in mRNA levels of IκB-α in zoledronate pre-treated cells, but had no effect on untreated cells ([Figure 4C](#f4-dddt-10-1453){ref-type="fig"}).

Discussion
==========

In this study, we investigated the effects of zoledronate in primary rat VSMCs on expression of three abundant MMPs that are known to influence their migration, proliferation, and apoptosis. We chose MMP-2, MMP-9, and MMP-13 since they show diverse substrate specificity and response to induction by PDGF plus TNF-α. Our data, for the first time, demonstrated that zoledronate induced expression of MMP-9 and MMP-13 but not MMP-2. Then, we investigated the possible underlying mechanisms and revealed that zoledronate may have a role in ROS production and activation of the NF-κB pathway.

As mentioned in the Introduction, bisphosphonates have been reported to inhibit expression and activity of some MMPs during cancer progression.[@b12-dddt-10-1453]--[@b14-dddt-10-1453] However, we found that zoledronate increased expressions of MMP-9 and MMP-13 in primary rat VSMCs, consonant with other published studies. For example, in a published study zoledronate administration before tooth extraction was stated to augment MMP-9 mRNA levels, protein expression of MMP-9, and enzymatic activity of MMP-9 during wound healing. The same study also reported that RANKL was at least partially responsible for the increased MMP-9 mRNA transcription.[@b24-dddt-10-1453] Similarly, pamidronate, another nitrogen containing bisphosphonate similar to zoledronate, at concentrations of 30 μM to 300 μM, caused a 5- to 10-fold increase in MMP-9 mRNA levels in human monocytes.[@b25-dddt-10-1453] Nitrogen containing bisphosphonate, alendronate markedly stimulated mRNA levels of MMP-13 in primary rat osteoblasts at concentrations higher than 10 μM.[@b26-dddt-10-1453] While these results support our basic findings, none of the published studies identified the underlying mechanisms.

We showed here that NF-κB activity is essential for up-regulation of MMP-9 and MMP-13 in rat VSMCs using the competitive inhibitor of κB kinase 2, SC-514.[@b20-dddt-10-1453] SC-514 can target other unrelated kinases PIM3, PIM1, DYRK1A, DYRK3, and Aurora B with similar affinity.[@b27-dddt-10-1453] However, MMP-1, MMP-3, and MMP-9 transcription in rabbit and human VSMCs[@b16-dddt-10-1453] was also inhibited by adenovirus-mediated gene transfer of dominant negative IκBα, which reinforces the specific role of NF-κB in MMP-9 induction. Similarly, NF-κB activation was shown to be essential for MMP-13 induction in chondrocytes.[@b28-dddt-10-1453]

We hypothesized, furthermore, that zoledronate can activate the NF-κB pathway. We found from preliminary experiments, that the effects of zoledronate required a 24-hour pre-incubation (results not shown). This implied that any activation of NF-κB would be slow and the method to detect it would need to be sensitive to prolonged activation. Acute activation is triggered by phosphorylation of IκBα which is then targeted for degradation by the 26S proteasome, allowing NF-κB dimers to translocate to the nucleus, usually within minutes, and activate transcription.[@b21-dddt-10-1453] Subsequently, one of the primary targets for active NF-κB is the IκBα gene, which drives re-synthesis of the IκBα protein and feeds back on the activation cascade.[@b21-dddt-10-1453] As a consequence, IκBα mRNA accumulates over an extended time period and we argued that this might provide a suitable measurement to investigate the effects of zoledronate. In fact, we found clear evidence that zoledronate pre-treatment increased IκBα mRNA and therefore slowly induced NF-κB activation. However, the findings from this study regarding NF-κB require further investigation, since the current study did not examine the protein expressions of NF-κB.

To answer the question regarding how zoledronate activated NF-κB, we set up additional experiment series in rat VSMCs. Our results from dichlorofluorescein experiments showed that zoledronate treatment increased ROS levels; and this finding was confirmed with an experiment on rat thoracic aortic rings by lucigenin measurements. Our evidences are consistent with previous experiments demonstrating bisphosphonate induced superoxide production in gastric and small intestinal epithelial cells.[@b29-dddt-10-1453] In addition, zoledronate administration (100 μg/kg subcutaneously for 28 days) caused increased oxidative stress and decreased antioxidant levels in rabbit livers.[@b30-dddt-10-1453] To confirm the role of oxidative stress in NF-κB activation and up-regulation of MMP-9 and MMP-13, we showed that apocynin, an inhibitor of NADPH oxidase, significantly inhibited these effects of zoledronate in VSMCs.

Our results provide new understanding regarding the pharmacological effects of bisphosphonates in the cardiovascular system. They are of particular relevance to pathologies, such as restenosis and vein graft intimal thickening, where there is a predominant role of VSMCs.[@b4-dddt-10-1453] Other sources of MMPs, such as macrophages, become relevant in the context of atherosclerosis,[@b4-dddt-10-1453] and it would be interesting, in future studies, to investigate how they respond to zoledronate treatment. Moreover, the NF-κB pathway has an established role in the induction of several MMPs in diverse cell types including: human epithelial cells,[@b31-dddt-10-1453] fibroblasts,[@b32-dddt-10-1453] and macrophages.[@b17-dddt-10-1453] It is therefore highly likely that the effects of zoledronate that we have identified here in rat VSMCs, apply more widely and could have a major impact on tissue remodeling and inflammatory activation caused by zoledronate. Further studies will be needed to address this interesting possibility.

In conclusion, our results conclusively demonstrate that zoledronate can increase expression of some MMPs in rat VSMCs. Furthermore, this is associated with stimulation of ROS production and consequent activation of the NF-κB pathway.
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![Effects of PDGF plus TNF-α and zoledronate (48 hours) on MMP-2, -9, and -13.\
**Notes:** (**A**) MMP-2 mRNA expression. \*\*\**P*≤0.001, \**P*≤0.05 vs Control-Untreated, n=3. (**B**) MMP-2 and MMP-9 protein expressions. A representative zymogram a: No induction; b: PDGF (50 ng/mL) + TNF-α-induced (10 ng/mL); c: PDGF (50 ng/mL) + TNF-α-induced (50 ng/mL). (**C**) MMP-9 mRNA expression. \*\**P*≤0.01, \*\*\**P*≤0.001 vs Control-untreated, ^\#\#^*P*≤0.01 vs control-zoledronate (n=3). (**D**) MMP-13 mRNA expression \*\**P*≤0.01, \*\*\**P*≤0.001 vs control untreated, ^\#\#^*P*≤0.01 vs control-zoledronate (n=3). (**E**) Protein expression of MMP-13 by Western blotting. Lanes No induction (c); Zoledronate (100 μM) (z); PDGF (50 ng/mL) + TNF-α-induced (50 ng/mL) (p+t); PDGF + TNF-α + Zoledronate (p+t+z).\
**Abbreviation:** EDTA, ethylenediaminetetraacetic acid.](dddt-10-1453Fig1){#f1-dddt-10-1453}

![Evidence for involvement of the NF-κB pathway.\
**Notes:** (**A**) Effects of IκB kinase 2 inhibitor SC-514 (50 μM) were measured on MMP-9 mRNA expression. \*\*\**P*≤0.001 untreated vs PDGF plus TNF-α induction, ^\#\#\#^*P*≤0.001 untreated vs SC-514 (n=4). (**B**) Effects of SC-514 (50 μM) were measured on MMP-13 mRNA expression. \*\*\**P*≤0.001 untreated vs PDGF plus TNF-α induction, ^\#\#\#^*P*≤0.001 untreated vs SC-514 (n=4). (**C**) Effects of PDGF plus TNF-α induction and zoledronate treatment (48 hours) were measured on IκBα mRNA expression levels. \*\*\**P*≤0.01 vs control -- untreated, ^\#^*P*≤0.05 untreated vs SC-514 (n=3).](dddt-10-1453Fig2){#f2-dddt-10-1453}

![Effects of zoledronate on ROS levels in rat VSMCs and aortic rings.\
**Notes:** (**A**) ROS levels determined by dichlorofluorescein (DCF) fluorescence were compared in control (c), PDGF (50 ng/mL) plus TNF-α (10 ng/mL) induced (pt) and zoledronate pre-treated (zol, 100 μM) cells. \**P*≤0.05 control vs zoledronate (n=4). (**B**) Lucigenin or luminol enhanced chemiluminescence was measured in control and 100 μM zoledronate pre-treated isolated rat aortic rings. \**P*≤0.05 control vs zoledronate, paired Student's *t*-test, (n=5).\
**Abbreviations:** ROS, reactive oxygen species; VSMCs, vascular smooth muscle cells; AUC, area under curve; RLU, relative light units.](dddt-10-1453Fig3){#f3-dddt-10-1453}

![Effects of apocynin with and without zoledronate on MMP-9, -13, and IκBα.\
**Notes:** (**A**) MMP-9 mRNA expression. \*\**P*≤0.01, ^\#^*P*≤0.05 vs control -- zoledronate. (**B**) MMP-13 mRNA expression. \**P*≤0.05, \*\*\**P*≤0.01 vs control -- untreated, ^\#^*P*≤0.05 vs control -- zoledronate. (**C**) IκBα mRNA expression. \**P*≤0.05 vs control -- untreated; ^\#^*P*≤0.05 control vs apocynin (n=4).](dddt-10-1453Fig4){#f4-dddt-10-1453}

###### 

Primer sequences used for real-time polymerase chain reaction

  Gene symbol   Accession number   Primer sequences
  ------------- ------------------ -------------------------------
  *MMP-2*       NM_031054          F: GGGAGCGCAAGGATGGAGGCACGA
                                   R: CCAGCAGGCAGCACAGGACGCAGA
  *MMP-9*       NM_031055          F: AGGCGCCGTGGTCCCCACTTACTT
                                   R: GCAGGGTTTGCCGTCTCCGTTGCC
  *MMP-13*      NM_133530          F: TCGCATTGTGAGAGTCATGCCAACA
                                   R: TGTGGTTCCAGCCACGCATAGTCA
  *IκB*         NM_001105720       F: CTACTGGACGACCGCCACGACAGC
                                   R: CGAGGCGGATCTCCTGCAGCTCCTTG
  *36B4*        NM_022402          F: GCCAGCGAAGCCACGCTGCTGAAC

**Note:** National Center for Biotechnology Information accession number, gene symbol, and sequences of forward (F) and reverse (R) primers.
